IMB-201 / IMBiologics - LARVOL DELTA

Innovative development of IMB-201, an anti-HLA-G antibody-drug conjugate (ADC), for enhanced tumor immunotherapy (AACR 2025) - "As HLA-G is a tumor-specific antigen, it has the potential to widen the therapeutic index (TI) compared to other conventional therapies. This strategy selectively targets tumor cells, delivering cytotoxic agents and enhancing immune response, thereby overcoming immune evasion mechanisms."

IO biomarker • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HLA-G

Novel and distinctive anti-HLA-G antibody, IMB-201, inhibits tumor progression by breaking immune escape mechanism and enhancing cytotoxicity (AACR 2024) - "Based on these results, IMB-201 could overcome the limitations of existing cancer immunotherapy, potentially becoming highly influential in cancer treatment as a novel immune checkpoint inhibitor. It is also expected to exhibit higher anticancer efficacy in combination therapy with immune checkpoint inhibitors."

IO biomarker • Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD8